Exicure, Inc. (XCUR) 10-K Summary: Fiscal Year Ended December 31, 2024
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2024. Exicure, Inc. is a Delaware corporation historically focused on nucleic acid therapies. In September 2022, the Company suspended all research and development (R&D) activities and began exploring strategic alternatives. As of the reporting date, the Company has no active R&D programs and no commercial product revenue. The business model has shifted to asset monetization and seeking strategic transactions or acquisitions to maximize stockholder value. In late 2024, the Company underwent a significant change of control, with HiTron Systems Inc. acquiring a majority stake.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0.5 million | $0 |
| Net Loss | $(9.7) million | $(16.9) million |
| Operating Expenses | $12.7 million | $15.0 million |
| Cash and Cash Equivalents (Year-End) | $12.5 million | $0.8 million |
| Stockholders' Equity | $6.8 million | $3.0 million |
| Accumulated Deficit | $(199.3) million | $(189.6) million |
Other Key Data:
- Debt: No long-term debt outstanding as of December 31, 2024. Short-term debt was converted to equity in September 2024.
- Liquidity: Cash position improved significantly due to equity financings in Q4 2024. Management states current liquidity is insufficient to fund operations for the next 12 months without additional financing.
- Employees: 7 full-time employees as of December 31, 2024 (down from prior years), focused on finance and general management.
Material Changes vs. Prior Period
- Revenue Generation: The Company recognized $0.5 million in revenue in 2024 from a patent license agreement, compared to zero in 2023. Additionally, $2.1 million in "Other Income" was recognized from the sale of clinical samples and historical biotechnology assets.
- Expense Reduction: Total operating expenses decreased by approximately 15% to $12.7 million. R&D expenses were $0 in 2024 compared to $1.4 million in 2023, as all R&D activities were halted. General and administrative expenses decreased by 53% due to reduced headcount and the absence of executive separation costs incurred in 2023.
- Impairment Losses: A one-time right-of-use asset impairment loss of $5.7 million was recorded in 2024 related to the Chicago office lease. In 2023, a $2.0 million loss was recorded for the impairment of convertible notes receivable.
- Capital Structure: The Company raised approximately $12.4 million in gross proceeds through common stock purchase agreements in November and December 2024. This included a change of control where HiTron Systems Inc. acquired 53% of outstanding shares.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: The Company is actively exploring strategic alternatives, including acquisitions and partnerships, potentially in industries unrelated to its historical biotechnology operations. It recently acquired GPCR Therapeutics USA Inc. in January 2025 (subsequent event). Management explicitly states there is substantial doubt about the Company's ability to continue as a going concern without additional financing.
Risks and Contingencies:
- Going Concern: The auditor has issued a "Going Concern" opinion. The Company requires substantial additional capital to fund operations and strategic exploration.
- Nasdaq Compliance: The Company faced multiple delisting notices regarding minimum bid price, stockholders' equity, and filing deadlines. It regained compliance as of December 17, 2024, but is subject to a one-year Mandatory Panel Monitor. Failure to maintain compliance could result in delisting.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, specifically regarding the review of non-routine activities and the design of accounting/IT controls. This led to the restatement of prior quarterly financial statements.
- Litigation: A securities class action lawsuit was settled in January 2025. The settlement is covered by insurance, but the Company accrued approximately $1.14 million for the unsatisfied self-insured retainer. Other derivative lawsuits remain stayed.
- Convertible Notes: The Company attempted to redeem $2.1 million in convertible notes receivable in 2024, but the issuer appears to have ceased operations. The investment is currently valued at $0.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure additional financing to sustain operations beyond the current cash runway of approximately $12.5 million.
- Nasdaq Listing: Monitor compliance with Nasdaq listing requirements, specifically the $2.5 million stockholders' equity rule, given the recent history of deficiency notices.
- Strategic Transaction Progress: Assess the likelihood and terms of the exploration of strategic alternatives or the integration of the recently acquired GPCR Therapeutics USA Inc.
- Internal Control Remediation: Review the progress of the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Convertible Note Recovery: Confirm the status of the $2.1 million investment in convertible notes receivable and the likelihood of any recovery.